Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.

Gregory Y H Lip; Lars H Rasmussen; Bertil Olsson; Eva Jensen; Bengt Hamrén; Ulf Eriksson; Karin Wåhlander

doi:10.1111/bcp.12719

Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.

Gregory Y H Lip, Lars H Rasmussen, Bertil Olsson, Eva Jensen, Bengt Hamrén, Ulf Eriksson, Karin Wåhlander

Cardiology

Research output: Contribution to journal › Article › peer-review

Abstract

AZD0837 is a novel oral anticoagulant investigated in clinical studies for stroke prevention in patients with atrial fibrillation (AF). It is bioconverted to its active form, AR-H067637, a potent, specific and reversible thrombin inhibitor.

Original language	English
Pages (from-to)	1362-1373
Journal	British Journal of Clinical Pharmacology
Volume	80
Issue number	6
DOIs	https://doi.org/10.1111/bcp.12719
Publication status	Published - 2015

Subject classification (UKÄ)

Pharmacology and Toxicology

Access to Document

10.1111/bcp.12719

http://www.ncbi.nlm.nih.gov/pubmed/26174611?dopt=Abstract

Cite this

@article{988d0c329c6a4a5db236ddf693b03a3e,

title = "Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.",

abstract = "AZD0837 is a novel oral anticoagulant investigated in clinical studies for stroke prevention in patients with atrial fibrillation (AF). It is bioconverted to its active form, AR-H067637, a potent, specific and reversible thrombin inhibitor.",

author = "Lip, {Gregory Y H} and Rasmussen, {Lars H} and Bertil Olsson and Eva Jensen and Bengt Hamr{\'e}n and Ulf Eriksson and Karin W{\aa}hlander",

year = "2015",

doi = "10.1111/bcp.12719",

language = "English",

volume = "80",

pages = "1362--1373",

journal = "British Journal of Clinical Pharmacology",

issn = "1365-2125",

publisher = "John Wiley & Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.

AU - Lip, Gregory Y H

AU - Rasmussen, Lars H

AU - Olsson, Bertil

AU - Jensen, Eva

AU - Hamrén, Bengt

AU - Eriksson, Ulf

AU - Wåhlander, Karin

PY - 2015

Y1 - 2015

N2 - AZD0837 is a novel oral anticoagulant investigated in clinical studies for stroke prevention in patients with atrial fibrillation (AF). It is bioconverted to its active form, AR-H067637, a potent, specific and reversible thrombin inhibitor.

AB - AZD0837 is a novel oral anticoagulant investigated in clinical studies for stroke prevention in patients with atrial fibrillation (AF). It is bioconverted to its active form, AR-H067637, a potent, specific and reversible thrombin inhibitor.

U2 - 10.1111/bcp.12719

DO - 10.1111/bcp.12719

M3 - Article

C2 - 26174611

SN - 1365-2125

VL - 80

SP - 1362

EP - 1373

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 6

ER -

Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this